Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.700
-0.060 (-3.41%)
At close: Apr 28, 2026, 4:00 PM EDT
1.730
+0.030 (1.76%)
After-hours: Apr 28, 2026, 6:16 PM EDT
Pyxis Oncology Employees
Pyxis Oncology had 56 employees as of December 31, 2025. The number of employees increased by 12 or 27.27% compared to the previous year.
Employees
56
Change (1Y)
12
Growth (1Y)
27.27%
Revenue / Employee
$247,464
Profits / Employee
-$1,421,804
Market Cap
106.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56 | 12 | 27.27% |
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Dec 31, 2021 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| Cibus | 118 |
| Immunic | 92 |
| Verrica Pharmaceuticals | 76 |
| Vivani Medical | 42 |
| Aardvark Therapeutics | 40 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 29 |
PYXS News
- 11 days ago - Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 - GlobeNewsWire
- 5 weeks ago - Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - GlobeNewsWire
- 4 months ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 4 months ago - Pyxis Oncology Transcript: Study Update - Transcripts
- 4 months ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 6 months ago - Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference - Transcripts
- 6 months ago - Pyxis Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Transcripts